CoChat

Utilizing CRISPR/Cas9 technology to prepare lymphoblastoid cell lines harboring genetic mutations for generating quality control materials in genetic testing

Open access
Zhou, Li, Li, Rui, Zhang, Runling, Peng, Rongxue, Chen, Kun, Gao, Peng, Zhang, Jiawei, Zhang, Rui, Li, Jinming · 2020 · Journal of Clinical Laboratory Analysis

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index; none of the 23 sources its claims cite is checked for support yet.

Abstract

Background: To meet the requirements of the rapidly progressing genetic testing technologies in clinical laboratories, assuring the quality of genetic tests by utilizing appropriate quality control materials is of paramount importance. The CRISPR/Cas9 technology was used to prepare quality control materials because genome‐edited human cell lines are one of the major resources for quality control materials. Methods: In this study, in vitro transcribed sgRNA were transfected into a Cas9‐expressing lymphoblastoid cell line (LCL)—by electroporation—to simulate the SEA‐type deletion observed in α‐thalassemia. The edited positive cell line was screened and identified by polymerase chain reaction (PCR) followed by Sanger sequencing. The whole‐genome sequencing was also performed to show evidence of predicted mutation. Results: The results showed that electroporation of the in vitro transcribed gRNAs into stable Cas9‐expressing LCL was a more efficient gene‐editing technique as compared to plasmid‐mediated transfection, and that the positive rates could reach up to 35.9%. The predominance of indel sizes relative to the predicted deletion length was clustered between 10 and 0 bp. The results of whole‐genome sequencing also demonstrated the existence of SEA‐type deletion of α‐thalassemia. Conclusions: Gene‐editing based on Cas9‐expressing LCL by electroporation of sgRNA was a more efficient approach to introduce mutations for generating quality control materials for genetic testing. The edited lymphoblastoid cell lines were feasible to serve as quality control materials in genetic testing.

Overview

CoChat Summary

TL;DR

This study used CRISPR/Cas9 to introduce a SEA-type α-thalassemia deletion into a Cas9-expressing lymphoblastoid cell line by electroporating in vitro transcribed sgRNAs, aiming to generate quality control materials for genetic testing. The edited cell lines were obtained efficiently and verified by PCR, Sanger sequencing, and whole-genome sequencing.

Key findings

  • Electroporation of in vitro transcribed gRNAs into stable Cas9-expressing LCL was more efficient than plasmid-mediated transfection: plasmid groups showed almost no indels, while gRNA transfection gave 10–30% indels by T7EI and positive rates up to 35.9% (28/78).
  • sgRNA A1/B1 had higher editing efficiency than sgRNA A2/B2: common editing efficiency was 35.9% (28/78) vs 19.2% (27/141); biallelic deletion was 24.4% vs 12.8%, and monoallelic deletion was 11.5% vs 6.4%.
  • Sanger sequencing showed indel sizes from −437 to +483 bp in mutant homozygotes and −100 to +1 bp in mutant heterozygotes, with the preponderance clustered between −10 and 0 bp; precise predicted deletion occurred in 15.8% (6/38) of biallelic and 41.2% (7/17) of monoallelic deletion alleles.
  • Whole-genome sequencing of one edited and two WT cell lines yielded 536 Gb of raw data, 255.20–393.46 million reads per clone, >94.85% mapped reads, and 47–72× genome coverage; it revealed a homozygous 19 kb deletion in chr16 consistent with PCR identification.

Methods

  • GM12878 cells stably expressing Cas9 and mCherry were cultured in RPMI 1640 with 15% FBS, streptomycin, and penicillin; sgRNAs were designed using CHOPCHOP for SEA-type α-thalassemia at chr16:165301–165501 and chr16:184401–185001, then in vitro transcribed.
  • In vitro transcribed gRNAs (12 µg) were electroporated into cells (2 × 10⁶ cells/mL) at 400 V for 30 ms using a 20 µL tube electroporator; editing was assessed by T7EI assay, single-cell sorting, PCR, and Sanger sequencing.
  • Genomic DNA from two WT cell lines and one Cas9-edited biallelic deletion line was sequenced on Gene+ Seq-2000 (paired-end 150 bp) with an average 35× sequencing depth; sequences were aligned using BLAST and visualized with IGV.

Limitations

  • The paper states that off-target effects may cause false-positive and negative results, and continuous Cas9/sgRNA expression could accumulate off-target sites over time; it also notes that the inserted Cas9 gene might affect DNA detection or genomic stability, though the authors argue this would not influence mutation detection and that genomic stability is comparable.
  • The paper states that tolerance for off-target effects varies by application, with therapeutic applications having much lower endurance than preparing QC materials, which are verified before use.
  • Evident from the text: validation focused on one SEA-type α-thalassemia deletion in GM12878 cells, and no genome-wide off-target analysis is reported despite whole-genome sequencing; generalizability to other mutations or cell lines is not demonstrated.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/jcla.23256

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 T7EI assay results and identification of the mutant genotype by traditional PCR. A, A wild type and B wild type mean the blank control group. The indel rates of each group were marked at the bottom of each electrophoresis band. The specific cutting bands caused by CRISPR/Cas9 cleavage was marked with red arrows. B, The genotype was identified by PCR using two sets of primers (AF/AR or AF/BR)
Figure 1 T7EI assay results and identification of the mutant genotype by traditional PCR. A, A wild type and B wild type mean the blank control group. The indel rates of each group were marked at the bottom of each electrophoresis band. The specific cutting bands caused by CRISPR/Cas9 cleavage was marked with red arrows. B, The genotype was identified by PCR using two sets of primers (AF/AR or AF/BR)CC BY-NC-ND · PubMed Central
Figure 2 Indels at the non‐deletion/non‐inversion allele and indels at the predicted deletion junction at the α globin gene locus. A,B, Sequencing of the monoallelic deletion allele in the compound deletion clones and biallelic deletion clones at the α globin gene locus by sgRNA A1/B1 and sgRNA A2/B2 are shown. The top row indicates the sequence of the unmodified allele. The sgRNA sequences are shown in green and the PAM sequences in purple and underlined. The deletion events are shown by an equivalent number of dash marks and insertions are highlighted in blue. The vertical lines indicate the predicted cleavage site between positions 17 and 18 of the sgRNA. The representative Sanger sequencing results of the mutant clones whose cleavage sites were exactly the same as those of the predicted cut sites
Figure 2 Indels at the non‐deletion/non‐inversion allele and indels at the predicted deletion junction at the α globin gene locus. A,B, Sequencing of the monoallelic deletion allele in the compound deletion clones and biallelic deletion clones at the α globin gene locus by sgRNA A1/B1 and sgRNA A2/B2 are shown. The top row indicates the sequence of the unmodified allele. The sgRNA sequences are shown in green and the PAM sequences in purple and underlined. The deletion events are shown by an equivalent number of dash marks and insertions are highlighted in blue. The vertical lines indicate the predicted cleavage site between positions 17 and 18 of the sgRNA. The representative Sanger sequencing results of the mutant clones whose cleavage sites were exactly the same as those of the predicted cut sitesCC BY-NC-ND · PubMed Central
Figure 3 The representative Sanger sequencing results of the mutant clones whose cleavage sites were the same as those of the predicted cut sites. A, showed an exact 18 999‐nt deletion existed at the PAM motifs junction generated by sgRNA A1/B1. B, showed an exact 19 117‐nt deletion existed at the PAM motifs junction generated by sgRNA A2/B2
Figure 3 The representative Sanger sequencing results of the mutant clones whose cleavage sites were the same as those of the predicted cut sites. A, showed an exact 18 999‐nt deletion existed at the PAM motifs junction generated by sgRNA A1/B1. B, showed an exact 19 117‐nt deletion existed at the PAM motifs junction generated by sgRNA A2/B2CC BY-NC-ND · PubMed Central
Figure 4 Indels at the α globin gene locus. A, The frequency distribution of indel formation at the predicted deletion junctions from the deleted alleles of monoallelic and biallelic deletion clones across the four loci was examined in detail. B, The distribution of indel formation at the predicted deletion junctions from the deleted alleles of deletion clones produced by sgRNA A and sgRNA B across the four loci was examined
Figure 4 Indels at the α globin gene locus. A, The frequency distribution of indel formation at the predicted deletion junctions from the deleted alleles of monoallelic and biallelic deletion clones across the four loci was examined in detail. B, The distribution of indel formation at the predicted deletion junctions from the deleted alleles of deletion clones produced by sgRNA A and sgRNA B across the four loci was examinedCC BY-NC-ND · PubMed Central
Figure 5 Whole‐genome sequencing analysis at sgRNA A/B target region of chr16 in two wild type and representative Cas9‐edited cell lines by Integrative Genomics Viewer (IGV). The pileup strip represents Cas9‐edited a homozygous deletion of 19 kb in chr16. Red arrows indicate DNA cleavage sites
Figure 5 Whole‐genome sequencing analysis at sgRNA A/B target region of chr16 in two wild type and representative Cas9‐edited cell lines by Integrative Genomics Viewer (IGV). The pileup strip represents Cas9‐edited a homozygous deletion of 19 kb in chr16. Red arrows indicate DNA cleavage sitesCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 11 Not checked · 33 Own results and interpretations

22 more claims

Create a free account to see all 44 claims and to verify the 22 references still open.

See all claims — free account
  • Probably not a substantial claim. 5
  • It may state two separate claims as one. 12

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Research works printed but not linked: 1

  1. https://www.ncbi.nlm.nih.gov/omim. Accessed November 5 2019.

Cited by

See all 4

Metadata

Authors
Zhou, L., Li, R., Zhang, R., Peng, R., Chen, K., Gao, P., Zhang, J., Zhang, R., & Li, J.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Beijing Hospital (CN)
Corresponding author
  • Zhang, Rui
  • Li, Jinming
Venue
Journal of Clinical Laboratory Analysis
Publisher
Wiley
Published
2020-03-02
Volume
34
Issue
7
Pages
e23256-e23256
ISSN
  • 0887-8013 (ISSN-L)
  • 1098-2825
OpenAlex
W3009396600
Cited by
4
References
28
Citations by year
2026: 1 · 2024: 2 · 2021: 1
FWCI
0.06
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Laboratory Analysis (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81871721)
  • Chinese Academy of Medical Sciences (2018RC320014)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Keywords
CRISPR/Cas9, lymphoblastoid cell lines, quality control materials, genetic testing, alpha-thalassemia, genome editing, electroporation, single guide RNA, whole genome sequencing
MeSH terms
Gene Editing, Whole Genome Sequencing, CRISPR-Associated Protein 9, RNA, Guide, CRISPR-Cas Systems, Cell Line, Genetic Testing, Humans, Mutation, Quality Control, Transfection, alpha-Thalassemia, Electroporation, High-Throughput Nucleotide Sequencing, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.